Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.58 |
| ▸ | ECE1 | P42892 | 3/20 | 0.58 |
| ▸ | CTSL | P07711 | 5/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | CASP9 | P55211 | 2/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13957718 | 0.93 | MME (0.64) | MMEECE1CTSLCTSKCASP1 | |
| SCHEMBL1426719 | 0.93 | MME (0.64) | MMEECE1CTSLCTSKCASP1 | |
| SCHEMBL13884435 | 0.93 | MME (0.64) | MMEECE1CTSLCTSKCASP1 | |
| SCHEMBL13589992 | 0.91 | ECE1 (0.63) | MMEECE1CTSLCASP1CASP3 | |
| SCHEMBL14433746 | 0.91 | ECE1 (0.63) | MMEECE1CTSLCASP1CASP3 | |
| SCHEMBL13884433 | 0.91 | ECE1 (0.63) | MMEECE1CTSLCASP1CASP3 | |
| SCHEMBL6552944 | 0.91 | ECE1 (0.63) | MMEECE1CTSLCASP1CASP3 | |
| SCHEMBL6552949 | 0.91 | ECE1 (0.63) | MMEECE1CTSLCASP1CASP3 | |
| SCHEMBL10397579 | 0.89 | MME (0.67) | MMEECE1CTSLCTSKNAALAD2 | |
| SCHEMBL13536734 | 0.89 | ITGB3 (0.63) | CTSLCTSKCTSBCTSSITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | MME 185/4885ECE1 415/4885CTSL 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.